Adaptimmune Therapeutics (ADAP) Competitors $0.25 +0.01 (+4.70%) Closing price 04:00 PM EasternExtended Trading$0.26 +0.00 (+1.65%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP vs. RNAC, ANNX, CGC, TSVT, DBVT, PVLA, CADL, CRDF, INZY, and IMMPShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Cartesian Therapeutics (RNAC), Annexon (ANNX), Canopy Growth (CGC), 2seventy bio (TSVT), DBV Technologies (DBVT), Palvella Therapeutics (PVLA), Candel Therapeutics (CADL), Cardiff Oncology (CRDF), Inozyme Pharma (INZY), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. Its Competitors Cartesian Therapeutics Annexon Canopy Growth 2seventy bio DBV Technologies Palvella Therapeutics Candel Therapeutics Cardiff Oncology Inozyme Pharma Immutep Cartesian Therapeutics (NASDAQ:RNAC) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk. Is RNAC or ADAP more profitable? Adaptimmune Therapeutics has a net margin of -38.91% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-510.72% N/A -7.01% Adaptimmune Therapeutics -38.91%-163.73%-23.65% Does the media favor RNAC or ADAP? In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 1 articles in the media. Adaptimmune Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.24 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptimmune Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, RNAC or ADAP? Adaptimmune Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M6.91-$77.42M-$52.83-0.20Adaptimmune Therapeutics$178.03M0.38-$70.81M-$0.27-0.94 Do analysts prefer RNAC or ADAP? Cartesian Therapeutics currently has a consensus target price of $41.25, indicating a potential upside of 298.17%. Adaptimmune Therapeutics has a consensus target price of $1.52, indicating a potential upside of 498.24%. Given Adaptimmune Therapeutics' higher possible upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Adaptimmune Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Which has more volatility & risk, RNAC or ADAP? Cartesian Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Does the MarketBeat Community prefer RNAC or ADAP? Adaptimmune Therapeutics received 290 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 63.39% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformCartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88%Adaptimmune TherapeuticsOutperform Votes32963.39% Underperform Votes19036.61% Do insiders and institutionals have more ownership in RNAC or ADAP? 87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCartesian Therapeutics beats Adaptimmune Therapeutics on 9 of the 17 factors compared between the two stocks. Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.25M$2.81B$5.19B$8.62BDividend YieldN/A2.72%5.38%4.23%P/E Ratio-0.9421.3025.6919.50Price / Sales0.38296.93400.43108.92Price / CashN/A42.0435.5255.95Price / Book5.087.438.015.60Net Income-$70.81M-$55.10M$3.15B$248.44M7 Day Performance-0.98%1.42%0.96%1.62%1 Month Performance-9.39%8.45%5.16%4.90%1 Year Performance-71.18%-1.41%38.42%16.62% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics2.6119 of 5 stars$0.25+4.7%$1.52+498.2%-72.8%$64.25M$178.03M-0.94490RNACCartesian Therapeutics1.4158 of 5 stars$10.32-1.0%$43.00+316.7%-56.9%$267.85M$34.17M-0.2064ANNXAnnexon2.0978 of 5 stars$2.44-2.0%$12.50+412.3%-52.2%$267.70MN/A-2.3260CGCCanopy Growth2.4408 of 5 stars$1.45-2.0%$2.00+37.9%-82.6%$266.60M$269.00M-0.383,150Gap UpTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440DBVTDBV Technologies2.9309 of 5 stars$9.55+4.9%$14.75+54.5%+76.5%$261.58M$15.73M-2.1280Gap UpPVLAPalvella Therapeutics3.3596 of 5 stars$23.42-6.5%$46.29+97.6%N/A$258.93M$42.81M-1.94N/ANews CoveragePositive NewsCADLCandel Therapeutics1.9185 of 5 stars$5.16+0.6%$21.00+307.0%-22.7%$258.53M$120K-2.9860News CoverageCRDFCardiff Oncology1.413 of 5 stars$3.86+1.3%$12.00+210.9%+29.0%$256.79M$587K-4.1120Positive NewsAnalyst ForecastGap UpINZYInozyme Pharma2.6851 of 5 stars$3.97-0.5%$11.75+196.0%-10.3%$256.31MN/A-2.5450IMMPImmutep0.8468 of 5 stars$1.71-1.7%$7.00+309.4%-44.5%$249.73M$5.14M0.002,021 Related Companies and Tools Related Companies RNAC Alternatives ANNX Alternatives CGC Alternatives TSVT Alternatives DBVT Alternatives PVLA Alternatives CADL Alternatives CRDF Alternatives INZY Alternatives IMMP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAP) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWall Street is using Bitcoin against youBitcoin is rising again, and institutions are pouring billions into Bitcoin ETFs. At first glance, that mig...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
